Stanley Druckenmiller's PTGX Position Overview
Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 159,700 shares of Protagonist Therapeutics, Inc. (PTGX) worth $13.95 M, representing 0.31% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Stanley Druckenmiller has initiated a new position in PTGX, representing a fresh investment thesis on this company.
Analysis based on 13F filings available since 2013 Q2
Stanley Druckenmiller's Protagonist Therapeutics (PTGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Protagonist Therapeutics (PTGX) Trades by Stanley Druckenmiller
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2025 | +159,700 | New Buy | 159,700 | $66.43 |
Stanley Druckenmiller's Protagonist Therapeutics Investment FAQs
Stanley Druckenmiller first purchased Protagonist Therapeutics, Inc. (PTGX) in Q3 2025, acquiring 159,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Stanley Druckenmiller has held Protagonist Therapeutics, Inc. (PTGX) for 2 quarters since Q3 2025.
Stanley Druckenmiller's largest addition to Protagonist Therapeutics, Inc. (PTGX) was in Q3 2025, adding 159,700 shares worth $10.61 M.
According to the latest 13F filing for Q4 2025, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 159,700 shares of Protagonist Therapeutics, Inc. (PTGX), valued at approximately $13.95 M.
As of the Q4 2025 filing, Protagonist Therapeutics, Inc. (PTGX) represents approximately 0.31% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.
Stanley Druckenmiller's peak holding in Protagonist Therapeutics, Inc. (PTGX) was 159,700 shares, as reported at the end of Q3 2025.